Budacan Alina-Maria, Patel Akshay J, Babu Pavithra, Khalil Haitham, Vaiyapuri Sumathi, Parry Michael, Kalkat Maninder S
Department of Thoracic Surgery, University Hospitals Birmingham, Birmingham, United Kingdom.
Department of Thoracic Surgery, University Hospitals Birmingham, Birmingham, United Kingdom; Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.
J Thorac Cardiovasc Surg. 2025 Apr;169(4):1120-1130.e1. doi: 10.1016/j.jtcvs.2024.09.035. Epub 2024 Sep 25.
We aimed to analyze survival, predictors of outcome, and the long-term functional status of patients with a diagnosis of primary chest wall sarcoma who undergo chest wall resection and reconstruction.
We analyzed a prospectively maintained database, including all patients operated on between 2008 and 2021. The primary outcome measures were overall and disease-free survival and analyses were employed to determine the risk factors for poor survival and recurrence.
One hundred thirty-nine patients were included, 55% were men. The majority (96%) had an R0 resection and 75.1% had no postoperative complications up to 30 days postprocedure; median length of hospital stay was 7 days (range, 6-10 days). Median overall and disease-free survival was 58.8 and 53.6 months, respectively. For those alive, at long-term follow-up, 80% had a Medical Research Council dyspnea score of 0 and Karnofsky index >80%. Survival and mortality rates were better in chondrosarcomas compared with nonchondromatous sarcomas (P < .05). Previous history of radiotherapy, previous history of cancer, the type of sarcoma (Ewing's or soft tissue), the need for adjuvant treatment and tumor grade were significant predictors of mortality and recurrence on univariate testing. Extended resection, a higher number of ribs removed, and the incidence of postoperative complications were significantly associated with a worse postoperative Medical Research Council dyspnea score.
Careful patient selection and multidisciplinary decision making is crucial. This leads to clear resection margins, good overall, and disease-free survival and good functional outcomes.
我们旨在分析诊断为原发性胸壁肉瘤并接受胸壁切除和重建的患者的生存率、预后预测因素以及长期功能状态。
我们分析了一个前瞻性维护的数据库,包括2008年至2021年间所有接受手术的患者。主要结局指标为总生存率和无病生存率,并进行分析以确定生存不良和复发的危险因素。
纳入139例患者,55%为男性。大多数(96%)患者实现R0切除,75.1%的患者术后30天内无并发症;中位住院时间为7天(范围6 - 10天)。总生存和无病生存的中位时间分别为58.8个月和53.6个月。在长期随访中,存活患者中有80%的医学研究委员会呼吸困难评分为0,卡诺夫斯基指数>80%。与非软骨肉瘤相比,软骨肉瘤的生存率和死亡率更高(P < 0.05)。单因素检验显示,既往放疗史、既往癌症史、肉瘤类型(尤因肉瘤或软组织肉瘤)、辅助治疗需求和肿瘤分级是死亡率和复发的重要预测因素。扩大切除、切除肋骨数量较多以及术后并发症的发生率与术后医学研究委员会呼吸困难评分较差显著相关。
仔细的患者选择和多学科决策至关重要。这会带来清晰的手术切缘、良好的总生存率和无病生存率以及良好的功能结局。